Verified Clinical Trials (VCT) protects your study — and your investment — by detecting duplicate subjects, professional patients, and other protocol violations at the time of screening, before they ever become costly problems.

Each screening visit, laboratory test, and randomization represents a significant financial and operational commitment. When an ineligible or poor-quality subject is enrolled, the downstream costs multiply — wasted visits, lost data, compromised endpoints, and the potential for study failure.

By identifying these issues in real time, VCT prevents unnecessary screening of ineligible participants and avoids the even greater expense of carrying a disqualified subject through the trial. Detecting and preventing even a small number of duplicate or noncompliant subjects typically offsets the entire cost of VCT — and in nearly every case, VCT saves substantial time and resources for the sponsor, CRO, and research sites.

In addition to financial efficiency, VCT helps sponsors and CROs avoid regulatory scrutiny that can arise from duplicate or overlapping enrollment. These issues often lead to questions about data reliability, delays in database lock, and postponed regulatory submissions or approvals. VCT’s cross-sponsor, cross-therapeutic verification process mitigates these risks by ensuring compliance and subject integrity from the outset.

VCT enables sponsors and CROs to:

• Prevent costly screening visits for ineligible or duplicate subjects.

• Reduce randomization errors that compromise study validity.

• Shorten timelines by preventing data-cleaning delays and database-lock issues.

• Minimize regulatory risk associated with duplicate enrollment and data inconsistency.

• Select better-quality subjects, improving protocol compliance and statistical power.

The cost of one failed or repeated trial can reach millions — but the cost to prevent it with VCT is minimal. The return on investment is immediate, and the value of protecting trial integrity is immeasurable.